Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines: A promising strategy for Osteosarcoma treatment

Copertina anteriore
Sapienza Universitą Editrice, 30 nov 2022 - 96 pagine

Osteosarcoma (OS) is the most aggressive type of primary solid tumor that develops in bone. Whilst conventional chemotherapy can improve survival rates, the outcome for patients with metastatic or recurrent OS remains poor, so novel treatment agents and strategies are required. Previously published works indicate that Agave exhibits anticancer properties. In the present study, anticancer effects of Agave leaf extract were investigated in the OS cells, discovering that Agave inhibits cell growth and cell migration, and sensitizes OS cells to cisplatin (CDDP), to overcome chemoresistance. Agave’s mechanisms of action include an initial process in which Agave induces YAP/TAZ oncogenic protein degradation, followed by a secondary event whereby Agave inhibits YAP/TAZ transcription through NF-κB p65:p50 heterodimers deregulation.

Winner of the Competition “Prize for PhD Thesis 2020” arranged by Sapienza University Press.

Dall'interno del libro

Pagine selezionate

Parole e frasi comuni

Informazioni sull'autore (2022)

Maria Ferraiuolo is a biologist experienced in Cancer Research, Viral Vector Production applied to vaccines development or gene therapy applications, and Clinical Research. She obtained her Master’s degree in 2014 and PhD degree in 2018. From 2012 to 2018 she worked at Regina Elena National Cancer Institute (IRE-IFO, Rome) in cancer research field, and in 2018 she moved to pharmaceutical environment becoming part of ReiThera’s team (Rome) until 2021, with the role of Senior process development scientist. Moved by an increasing interest in Clinical Research, she joined the CRO PRA Health Sciences’ team (Milan) acting as Site Activation Specialist since 2021.

Informazioni bibliografiche